Zila Cites Second Study Linking Ester-E(R) To Healthy Cardiovascular Function
October 20 2005 - 9:47AM
Business Wire
Zila, Inc. (Nasdaq:ZILA) today commented on a study conducted for
the Australian company, Phosphagenics Limited, that confirms an
earlier study suggesting that Ester-E(R) may proactively benefit
cardiovascular health. In this animal study, Ester-E(R)
significantly reduced LDL-C (so-called bad cholesterol),
triglycerides, and plaque formation, while regular vitamin E had no
significant effect. Zila Nutraceuticals, Inc., a wholly owned
subsidiary of Zila, Inc., has an exclusive license to the patented
Phosphagenics vitamin E technology within the dietary supplement
category and currently produces and distributes Ester-E(R) in the
United States. The study data showed that this unique form of
vitamin E lowered bad cholesterol concentrations in blood by up to
44% and triglycerides by up to 51% in mice fed normal diets. When
fed high cholesterol diets, Ester-E(R) significantly reduced plaque
formation in the aorta by 58%. Again, regular vitamin E had no
significant effect on plaque formation. These results confirm the
earlier animal study indicating that Ester-E(R) may have the
potential to yield healthier levels of total cholesterol,
triglycerides and LDL-C in humans. The animal model chosen for the
trials is commonly used in cardiovascular research as it mimics
many of the properties observed clinically in humans. "We are
encouraged that these results support the earlier animal study.
Based on these animal studies, as well as earlier in vitro studies,
we are confident in the potential of Ester-E(R) to support
cardiovascular health in humans," said Larry E. Robinson, Ph.D.,
Vice President of Scientific Affairs for Zila Nutraceuticals, Inc.
"We are very pleased with these results as we continue to push
forward with research into the benefits of Ester-E(R)," added
Douglas D. Burkett, Ph.D., Chairman, Chief Executive Officer and
President of Zila, Inc. "We are conducting our own Ester-E(R)
clinical trial in humans to provide further support for the
product's health benefits, including its effect on cardiovascular
health. We look forward to reporting on those results upon the
completion of the trial." "Zila is committed to the growth of our
nutraceutical business by developing and bringing to market a line
of superior efficacy dietary supplements that promote the health of
consumers globally under the well-known Ester brand name,"
concluded Burkett. A copy of Phosphagenics' news release announcing
the results of the original study can be found at
www.phosphagenics.com. For more information about Ester-E(R), visit
www.ester-e.com. Ester-E(R) is the registered trademark of Zila
Nutraceuticals, Inc. Information and statements regarding dietary
supplements have not been evaluated by the Food and Drug
Administration and are not intended to diagnose, treat, cure, or
prevent any disease. This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on Zila's
expectations or forecasts of future events, can be affected by
inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, margins,
profitability, cash flows and capital needs, the ability of the
Company to maintain required cash flows and cash availability to
implement its business plan and appreciation in the market value of
Zila's common stock. Such factors include, but are not limited to:
increased competition from current competitors and new market
entrants; the Company's ability to maintain, expand, or in certain
cases, regain distribution within new or existing channels of trade
for its products. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Report on Form 10-K
for its fiscal year ended July 31, 2005, filed with the Securities
and Exchange Commission.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024